https://www.selleckchem.com/pr....oducts/agi-24512.htm
This study reveals an HSP90-centric, iron-modulated mechanism that confers immunosuppression, offering potential therapeutic targets for interfering with acquired resistance to the most prevalent anticancer immunotherapies. This study reveals an HSP90-centric, iron-modulated mechanism that confers immunosuppression, offering potential therapeutic targets for interfering with acquired resistance to the most prevalent anticancer immunotherapies. In an exploratory analysis, we investigated the association between programmed death ligand
Like
Comment
Share
